SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Chonluten	Vesugen	Thymosin Alpha-1
Research Topic	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology	Longevity / Aging Research
Pharmacology	EDG tripeptide / experimental inflammatory signalling	KED tripeptide / experimental cell signalling	Synthetic N-terminal acetylated 28-amino-acid immunomodulatory peptide
PrimeCore Class	Class CExperimental / limited evidence	Class CExperimental / limited evidence	Class AApproved in a bounded context
Evidence Grade	Grade EPreclinical evidence	Grade EPreclinical evidence	Grade BStrong controlled human evidence
Evidence boundary	The 2022 THP-1 study identifies Chonluten as EDG. Its cell-signalling and TNF findings do not establish treatment of asthma, COPD or lung injury. Chonluten must not inherit evidence from Bronchogen or different vendor sequences.	Vesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials.	A synthetic immunomodulatory peptide with jurisdiction-specific medicine status and indication-bounded clinical evidence.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	which biomarker-defined subgroups, if any, derive clinically meaningful benefit comparative benefit against current standard-of-care therapies for each indication long-term safety in autoimmune, transplant and oncology populations equivalence of free base, acetate and marketed/compounded formulations quality and immunogenicity of product-specific compounded preparations current Thai marketing-authorisation status
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) EDG ใน cell-line study ≠ Bronchogen tetrapeptide ≠ ยารักษาโรคปอด; ผล TNF ไม่ใช้รับรอง immune boosting	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) การเปลี่ยน marker ของเซลล์หลอดเลือดไม่เท่ากับลดหัวใจวายหรืออัมพาต และไม่เท่ากับยาลดความดัน	The evidence spans different indications, eras, background therapies, formulations and jurisdictions. Many positive studies are small, single-blind, observational or use outdated comparators. The most rigorous recent sepsis trial was negative. FDA found insufficient effectiveness across the nominated compounding uses and substantial product-characterization and safety gaps; foreign approval cannot be generalized beyond its label.
Sources	THP-1 signalling study · PMID 35408963	Endothelial cultures and docking · PMID 25051766 Differentiation markers · PMID 22808515	https://medicinali.aifa.gov.it/it/#/it/dettaglio/0000022315 https://www.drugoffice.gov.hk/eps/drug/productDetail2/en/consumer/155704 https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Antimicrobial%20%26%20Antiviral%20dated%2009.05.2024.pdf https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalMarketingFDC/sndapprovjuly.pdf https://www.fda.gov/media/183820/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://pubmed.ncbi.nlm.nih.gov/39814420/ https://clinicaltrials.gov/study/NCT02867267 https://pubmed.ncbi.nlm.nih.gov/23327199/ https://clinicaltrials.gov/study/NCT00711620 https://pubmed.ncbi.nlm.nih.gov/40969554/ https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://products.mhra.gov.uk/
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.